Rigel Pharmaceuticals (RIGL) Cash from Operations (2010 - 2026)

Rigel Pharmaceuticals' Cash from Operations history runs 17 years deep, the most recent figure standing at 2725000.0 for Q1 2026.

• In Q1 2026, Cash from Operations rose 405.15% year-over-year to 2725000.0; the TTM figure through Mar 2026 stood at 79273000.0 (up 122.73% YoY), while the FY2025 annual figure was 75655000.0, up 140.4% from the prior year.
• Cash from Operations was 2725000.0 for Q1 2026 at Rigel Pharmaceuticals, down from 21980000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 30537000.0 in Q2 2025 to a low of 25637000.0 in Q1 2022.
• Historically, Cash from Operations has averaged 1785294.12 across 5 years, with a median of 893000.0 in 2025.
• The sharpest annual moves came in 2022 and 2025: Cash from Operations sank 123.38% in 2022, then soared 10011.59% in 2025.
• A 5-year view of Cash from Operations shows it stood at 21909000.0 in 2022, then surged by 71.52% to 6240000.0 in 2023, then soared by 332.42% to 14503000.0 in 2024, then jumped by 51.55% to 21980000.0 in 2025, then plunged by 87.6% to 2725000.0 in 2026.
• The last three Cash from Operations figures came in at 2725000.0 (Q1 2026), 21980000.0 (Q4 2025), and 24031000.0 (Q3 2025), per Business Quant data.